Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

BACKGROUND: The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP and to elucidate the sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Kazuhiko, Ohta, Shigeyuki, Komatsu, Kenji, Kubo, Taro, Nukui, Akinori, Suzuki, Kazumi, Kurokawa, Shinsuke, Kobayashi, Minoru, Morita, Tatsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305626/
https://www.ncbi.nlm.nih.gov/pubmed/22353627
http://dx.doi.org/10.1186/1471-2490-12-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305626/
https://www.ncbi.nlm.nih.gov/pubmed/22353627
http://dx.doi.org/10.1186/1471-2490-12-3

Ejemplares similares